Acute ischemic stroke
Conditions
Interventions
Endovascular treatment + tirofiban group:Treated with tirofiban. Dosage of tirofiban: Arterial administration of tirofiban, intravenous continuation until 24 hours of onset. Antithrombotic drugs were
Endovascular treatment + placebo group:Placebo treatment with tirofiban, the usage is the same as that of tirofiban. Antithrombotic drugs were administered according to guidelines after the 24th hour
Sponsors
The Second Affiliated Hospital of the Army Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age>=18 years old; 2. Preliminary judgment of acute ischemic stroke based on clinical symptoms or imaging examination; 3. Acute ischemic stroke confirmed by cranial imaging and basilar artery occlusion (including isolated vertebral artery V4 segment and distal occlusion); 4. NIHSS score >=6 points; 5. PC-ASPECTS score >=5 points; 6.mTICI>=2b; 7. The time from onset to randomization is within 24 hours; 8. Signed written informed consent by the patient or family member.
Exclusion criteria
Exclusion criteria: 1. Intracranial hemorrhage confirmed by head CT or MRI; 2. The mRS score before the onset of the disease >= 2 points; 3. Antiplatelet aggregation therapy is planned during and after surgery; 4. Pregnant or lactating women; 5. Genetic or acquired hemorrhagic constitution, anticoagulant factor deficiency; or have used anticoagulants with an INR > 1.7; 6. Blood glucose 22.2mmol/L, platelet < 90*10^9/L; 7. Life expectancy of < 6 months due to any advanced disease; 8. Expected inability to complete follow-up; 9. Intracranial aneurysm, arteriovenous malformation; 10. Intracranial mass lesions; 11. Patients with severe hepatic and renal insufficiency; 12. Participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement of mRS scores;Incidence of symptomatic intracranial hemorrhage (Sich) within 48h and 90 day mortality; | — |
Secondary
| Measure | Time frame |
|---|---|
| mRS scores 0-2 (%);mRS scores 0-3 (%);NIHSS score 5-7 days after medication, if the time of discharge is earlier than 5-7 days, the time of discharge shall prevail;90-day EQ-5D scale score;Incidence of asymptomatic intracranial hemorrhage (aSICH) within 48h;Complication rate of non intracranial hemorrhage (including gastrointestinal bleeding, urethral bleeding, oral or nasal mucosal bleeding, subcutaneous hematoma, etc.);Incidence of non hemorrhagic serious adverse events (including cerebral hernia, pneumonia, respiratory failure, circulatory failure, stress ulcer, secondary epilepsy, urinary tract infection, sepsis, renal failure, acute coronary syndrome, venous thrombosis and psychiatric symptoms);Thrombocytopenia (defined as platelet count <90*10^9 /l in blood routine examination within 48h after medication); | — |
Countries
China
Contacts
Public ContactWenjie Zi
Department of Neurology, Xinqiao Hospital The Second Affiliated Hospital of the Army Medical University
Outcome results
None listed